We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
11
Research Clients
180
Reports published
10k+
Readers in database
Our Outlook note provides a recap on @MaxCyte_info ’s #flowelectroporation technology, & broad suit of licences, which places it at the heart of many developmental #celltherapies, including its own #CARMA platform. $MXCT Read more at https://www.trinitydelta.org/company-pages/
Expected newsflow from @BGenBio Q120 update includes data presentations from #bemcentinib #AML & #NSCLC trials at conferences, as well as first data from #ACCORD #COVID19 trial $BGBIO
Data on 1st 3 dose cohorts from @MaxCyte_info lead #CARMA programme MCY-M11 Phase I study to be presented at #ASCO20 $MXCT
https://otp.tools.investis.com/clients/uk/maxcyte1/rns/regulatory-story.aspx?cid=1311&newsid=1391003
Key @HChiMed presentations at #ASCO20 include #savolitinib data from (1) #SAVOIR Phase III #PRCC & (2) Ph II MET ex14m #NSCLC studies; and #surufatinib data in US #NET patients $HCM
Recent MET developments incl 1st global MET inhibitor approval (@merckgroup #tepotinib in Japan) & 1st approved by FDA (@Novartis #capmatinib) both for MET ex14m #NSCLC. @AstraZeneca /@HChiMed on track to file #savolitinib China NDA in same indication mid-2020 (& data at #ASCO20)
$AGL’s @parsortix #liquidbiopsy shows potential utility in assessing MET alterations on circulating tumour cells
'Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients' @MDPIOpenAccess https://www.mdpi.com/2073-4409/9/2/522
Please sign up here to be added to our distribution database
